MEARY Center partner of GENOTHER
Genother, excellence in gene therapy, named Biocluster of the France 2030 Program.
The founders of the Genother project - Genethon, Genopole, AP-HP, Inserm, Université d'Évry Paris-Saclay, Spark Therapeutics, Yposkesi - are delighted that it has been approved by the French National Research Agency on May 16, 2023 as part of the "Biocluster" call for expressions of interest under the France 2030 program. Genother will enable France to expand its European leadership in the development and production of gene therapies, which is essential to its health independence in one of the most dynamic fields of biomedical research. Indeed, 24 gene therapy drugs are currently approved by health authorities worldwide, 3,000 products are under development, and by 2025, 20% of new registered products will be based on gene therapy technologies. This labeling marks a major step in the creation of a unique ecosystem in Europe to meet the scientific, technological and economic challenges associated with these innovative therapies.
Genother is the result of the will of its founders, who represent the vanguard and the excellence of R&D in gene therapy and, together with the many players involved, constitute a unique strike force that includes 2,000 researchers and clinicians, 10,000 publications, more than 2,000 patents and more than 40 licensing agreements, 50 clinical programs and 15 spin-offs in this field. The biocluster will enable the creation and development of dozens of companies, from research to industrialization. It will attract the best talent and accelerate R&D projects. The ambition is to develop a dozen gene therapies for rare and frequent diseases.
The creation of Genother is a strong signal to the scientific, medical and industrial communities that France is a leader in the development of innovative therapies and medicines and in clinical trials in this field.
The biocluster label is also a major asset for strengthening France's competitiveness and attractiveness in this innovative field of medicine, which is crucial for our country's health independence and economic development. Genother will focus on several areas, drawing on the unique expertise of its founders and members: - The development of cutting-edge technological platforms, from research to industrial production - The development of next-generation gene and cell therapy technologies, integrating cutting-edge in vivo and ex vivo genome editing approaches, and RNA-based therapies, allowing for the further expansion of the fields of application of these approaches - Disruptive innovation in the field of biomanufacturing to drastically reduce the production costs of biomedicines and make them accessible to the greatest number of people.
Sharing clinical excellence: renewed databases and the development of innovative tools for conducting clinical trials will accelerate the development of therapeutic solutions.
Training and development of skills through dedicated courses in research, development, biomanufacturing and entrepreneurship Genother brings together 7 founders and 12 partners.
It is strongly supported by local authorities, various research support organizations and biotechnology players.
Partners: AFM-Téléthon, Institut Imagine, Institut de Myologie (AIM), Université Paris-Est Créteil (UPEC), Thales, Samabriva, Polytheragen, Toulouse Biotech Institute, Whitelab Genomics, ESPCI (Ecole Supérieure de Physique et Chimie Industrielles), CentraleSupélec, IMT Group (Institut de Formation Professionnelle Industrielle) Soutiens actifs : France Biotech, Fondation Maladies Rares, Genosafe, Centre Hospitalier Sud Francilien, RD-Biotech, GTP Bioways, Evry-Courcouronnes, Grand Paris Sud, département de l’Essonne, Région Ile-de-France, Université Paris Saclay, Ipsen, Atamyo, Ampleia, Kurma, AdBio, General Inception.
